VHL Polyclonal Antibody
Product Specifications
Background
Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
CAS Number
9007-83-4
Synonyms
Von Hippel-Lindau disease tumor suppressor ;Protein G7;pVHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL
Host
Rabbit
Reactivity
Human, Rat, Mouse
Immunogen
The antiserum was produced against synthesized peptide derived from the N-terminal region of human VHL. AA range:1-50
Clonality
Polyclonal
Applications
IHC-p, IF, ELISA
Stability
-20°C for 1 year
Concentration
1 mg/ml
Antibody Type
Primary antibody
Isotype
IgG
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog